

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-9 (Cancelled)

10. (Previously presented) A method of monitoring the progression of cancer in a patient comprising:

- (a) determining the level of podocalyxin in a sample from the patient;
- (b) repeating step (a) at a later point in time and comparing the result of step (a) with the result of step (b) wherein a difference in the level of podocalyxin is indicative of the progression of the cancer in the patient.

11. (Cancelled)

12. (Currently amended) A method of determining whether or not a cancer is metastatic ~~or at risk of metastasis~~ in a patient or whether the patient having said cancer has a poor outcome comprising:

- (a) detecting the level of podocalyxin in a sample from the patient; and
- (b) comparing the level of podocalyxin in the sample to a control sample from non-metastatic cancer, wherein an increased level of podocalyxin as compared to the control indicates that the cancer is metastatic ~~or at risk of metastasis~~ the patient having said cancer has a poor outcome.

13-33 (Cancelled)

34. (Previously presented) A method according to claim 10 or 12 wherein the cancer is breast cancer.

35. (Previously presented) A method according to claim 10, 12 or 34 wherein determining the level in step (a) comprises determining the amount of nucleic acid molecules.

36. (Previously presented) A method according to claim 35 wherein the nucleic acid molecules are mRNA.

37. (Previously presented) A method according to claim 10, 12 or 34 wherein determining the level in step (a) comprises determining the amount of protein.

38. (Previously presented) A method according to claim 37 wherein an antibody is used to determine the levels of the protein.

39. (Previously presented) A method according to claim 10, wherein the patient is undergoing treatment and an increase in podocalyxin is indicative that the treatment is not effective.

40-45 (Cancelled)